Senseonics (NASDAQ:SENS) Shares Down 6.4% – Time to Sell?

Senseonics Holdings, Inc. (NASDAQ:SENS – Get Free Report) traded down 6.4% during mid-day trading on Thursday. The company traded as low as $9.10 and last traded at $9.1150. 582,988 shares were traded during trading, a decline of 18% from the average session volume of 707,141 shares. The stock had previously closed at $9.74.

Wall Street Analysts Forecast Growth

SENS has been the subject of several recent analyst reports. Stifel Nicolaus restated a “hold” rating and issued a $10.00 price target (up from $9.00) on shares of Senseonics in a report on Tuesday, November 10th. Raymond James Financial upgraded Senseonics from an “underperform” rating to a “market perform” rating in a report on Tuesday, November 10th. HC Wainwright reiterated a “buy” rating and issued a $14.00 price target on shares of Senseonics in a research note on Tuesday, November 10th. Mizuho increased their price target on shares of Senseonics from $18.00 to $20.00 and gave the stock an “outperform” rating in a research report on Tuesday, November 10th. Finally, Weiss Ratings upgraded Senseonics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, November 4th. Three equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $14.40.

Get Our Latest Research Report on SENS

Senseonics Stock Performance

The firm’s fifty day simple moving average is $9.22 and its 200 day simple moving average is $7.38. The company has a market capitalization of $437.69 million, a price-to-earnings ratio of -3.47 and a beta of 1.04. The company has a debt-to-equity ratio of 0.70, a current ratio of 5.92 and a quick ratio of 5.60.

Senseonics (NASDAQ:SENS – Get Free Report) last posted its quarterly earnings data on Monday, November 9th. The company reported ($0.50) earnings per share for the quarter, missing the consensus estimate of ($0.49) by ($0.01). The company had revenue of $19.56 million during the quarter. Senseonics had a negative net margin of 204.01% and a negative return on equity of 186.11%. On average, sell-side analysts forecast that Senseonics Holdings, Inc. will post -2.20 EPS for the current year.

Insider Buying and Selling

In other Senseonics news, Director Douglas Roeder bought 17,041 shares of the stock in a transaction on Friday, November 13th. The stock was purchased at an average price of $10.32 per share, with a total value of $175,863.12. Following the acquisition, the director owned 189,712 shares of the company’s stock, valued at approximately $1,957,827.84. The trade was a 9.87% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 4.70% of the company’s stock.

Institutional Investors Weigh In On Senseonics

Several hedge funds have recently bought and sold shares of SENS. State of Wyoming lifted its stake in Senseonics by 27.2% in the 3rd quarter. State of Wyoming now owns 14,940 shares of the company’s stock valued at $152,000 after acquiring an additional 3,199 shares in the last quarter. Integrated Wealth Concepts LLC bought a new position in shares of Senseonics in the 2nd quarter valued at about $36,000. Kestra Advisory Services LLC acquired a new stake in shares of Senseonics in the first quarter valued at about $68,000. The Manufacturers Life Insurance Company bought a new stake in Senseonics during the second quarter worth about $65,000. Finally, StoneX Group Inc. bought a new stake in Senseonics during the third quarter worth about $128,000. 12.36% of the stock is currently owned by institutional investors and hedge funds.

About Senseonics

(Get Free Report)

Senseonics Holdings, Inc. develops continuous glucose monitoring (CGM) technology for people with diabetes. Its Eversense systems use a small sensor implanted under the skin to measure glucose levels, an external wearable transmitter to send readings, and a mobile app to display data and provide alerts. The company’s product line includes implantable CGM systems designed for extended wear, including the Eversense 365 system, which is designed to last up to one year. Unlike many CGM products that use sensors replaced more frequently, Eversense sensors are inserted and removed by a healthcare professional.

Recommended Stories

Receive News & Ratings for Senseonics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Senseonics and related companies with MarketBeat.com's FREE daily email newsletter.